Literature DB >> 21915053

The association of prior statin use in septic shock treated with early goal directed therapy.

Brian M Fuller1, Mithil Gajera, Christa Schorr, David Gerber, R Phillip Dellinger, Sergio Zanotti.   

Abstract

BACKGROUND: Previous literature suggests statins may have a therapeutic role in sepsis. No data have examined if statin use may have a positive impact beyond that afforded by early goal directed therapy (EGDT).
OBJECTIVE: To test the hypothesis that previous statin use is associated with improved clinically relevant outcomes in patients with severe sepsis and septic shock receiving EGDT.
METHODS: Retrospective cohort study of 91 patients who presented in an academic center in severe sepsis or septic shock and received EGDT. Primary outcome was mortality and secondary outcomes included mechanical ventilation days, ICU length of stay, and hospital length of stay.
RESULTS: Patients (87 of 91) presented to the Emergency Department before ICU admission. Patients (18 of 91) were receiving statin therapy before presentation. The statin group had a mortality rate of 22.2 vs. 39.7% in the nonstatin group (P=0.273). The statin group had fewer mechanical ventilation days (8.49 vs. 7.29 days, P=0.026), and a trend in improved hospital length of stay (17.9 vs. 14.4 days, P=0.065), and ICU length of stay (7.15 vs. 4.89 days, P=0.077).
CONCLUSION: Prior statin use is associated with fewer mechanical ventilation days and a trend toward improvement in other clinically relevant outcomes. This trial is limited by its retrospective nature and small sample size. These results should serve as hypothesis generating for future prospective trials, as the lack of novel drug therapy and the mortality rate of septic shock both remain unacceptable.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 21915053      PMCID: PMC3556478          DOI: 10.1097/MEJ.0b013e32834b3467

Source DB:  PubMed          Journal:  Eur J Emerg Med        ISSN: 0969-9546            Impact factor:   2.799


  40 in total

1.  Early goal-directed therapy in the treatment of severe sepsis and septic shock.

Authors:  E Rivers; B Nguyen; S Havstad; J Ressler; A Muzzin; B Knoblich; E Peterson; M Tomlanovich
Journal:  N Engl J Med       Date:  2001-11-08       Impact factor: 91.245

2.  In vivo anti-inflammatory effect of statins is mediated by nonsterol mevalonate products.

Authors:  L Diomede; D Albani; M Sottocorno; M B Donati; M Bianchi; P Fruscella; M Salmona
Journal:  Arterioscler Thromb Vasc Biol       Date:  2001-08       Impact factor: 8.311

3.  Epidemiology of severe sepsis in the United States: analysis of incidence, outcome, and associated costs of care.

Authors:  D C Angus; W T Linde-Zwirble; J Lidicker; G Clermont; J Carcillo; M R Pinsky
Journal:  Crit Care Med       Date:  2001-07       Impact factor: 7.598

4.  Rapid reduction in C-reactive protein with cerivastatin among 785 patients with primary hypercholesterolemia.

Authors:  P M Ridker; N Rifai; S P Lowenthal
Journal:  Circulation       Date:  2001-03-06       Impact factor: 29.690

5.  Efficacy and safety of recombinant human activated protein C for severe sepsis.

Authors:  G R Bernard; J L Vincent; P F Laterre; S P LaRosa; J F Dhainaut; A Lopez-Rodriguez; J S Steingrub; G E Garber; J D Helterbrand; E W Ely; C J Fisher
Journal:  N Engl J Med       Date:  2001-03-08       Impact factor: 91.245

6.  The effect of statins on mortality in patients with bacteremia.

Authors:  A P Liappis; V L Kan; C G Rochester; G L Simon
Journal:  Clin Infect Dis       Date:  2001-09-20       Impact factor: 9.079

7.  HMG CoA reductase inhibitors reduce plasminogen activator inhibitor-1 expression by human vascular smooth muscle and endothelial cells.

Authors:  T Bourcier; P Libby
Journal:  Arterioscler Thromb Vasc Biol       Date:  2000-02       Impact factor: 8.311

8.  Atorvastatin activates PPAR-gamma and attenuates the inflammatory response in human monocytes.

Authors:  O Grip; S Janciauskiene; S Lindgren
Journal:  Inflamm Res       Date:  2002-02       Impact factor: 4.575

9.  Cerivastatin improves survival of mice with lipopolysaccharide-induced sepsis.

Authors:  H Ando; T Takamura; T Ota; Y Nagai; K Kobayashi
Journal:  J Pharmacol Exp Ther       Date:  2000-09       Impact factor: 4.030

10.  Simvastatin decreases lipopolysaccharide-induced pulmonary inflammation in healthy volunteers.

Authors:  Murali Shyamsundar; Scott T W McKeown; Cecilia M O'Kane; Thelma R Craig; Vanessa Brown; David R Thickett; Michael A Matthay; Clifford C Taggart; Janne T Backman; J Stuart Elborn; Daniel F McAuley
Journal:  Am J Respir Crit Care Med       Date:  2009-03-26       Impact factor: 21.405

View more
  2 in total

1.  Effect of the use of low and high potency statins and sepsis outcomes.

Authors:  Shu-Yu Ou; Hsi Chu; Pei-Wen Chao; Shuo-Ming Ou; Yi-Jung Lee; Shu-Chen Kuo; Szu-Yuan Li; Chia-Jen Shih; Yung-Tai Chen
Journal:  Intensive Care Med       Date:  2014-08-05       Impact factor: 17.440

2.  Survival benefit of a low ratio of visceral to subcutaneous adipose tissue depends on LDL clearance versus production in sepsis.

Authors:  Joseph G H Lee; Kelly R Genga; Chawika Pisitsak; John H Boyd; Alex K K Leung; James A Russell; Keith R Walley
Journal:  Crit Care       Date:  2018-03-06       Impact factor: 9.097

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.